Tilly's, Inc. Announces Appointment of Nate Smith as President and Chief Executive Officer Beginning August 18, 2025.

Stock Information for Regulus Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Regulus Therapeutics Inc.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Tilly's, Inc. (NYSE: TLYS)
Tilly's, Inc. Exceeds Fiscal 2025 Third Quarter Earnings Outlook
Tilly's, Inc. to Report Fiscal 2025 Third Quarter Operating Results on December 3, 2025
Tilly's, Inc. Reports Fiscal 2025 Second Quarter Operating Results
Tilly's, Inc. to Report Fiscal 2025 Second Quarter Operating Results on September 3, 2025
Tilly's, Inc. Selects Impact Analytics as Strategic AI Partner for Inventory Optimization and Business Intelligence
Tilly's, Inc. Reports Fiscal 2025 First Quarter Operating Results
Tilly's Partners with Nedap to Elevate Omnichannel Strategy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.